$88 Million: Medical Company Reports Promising Skin Disorder Treatment

VYNE Therapeutics Achieves Promising Phase 1b Trial Results for BET Inhibitor VYN201, Revealing Hope for Nonsegmental Vitiligo Patients.

This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

VYNE Therapeutics, a leading pharmaceutical company, has recently reported positive data from its Phase 1b clinical trial for its novel Bromodomain and Extra-Terminal motif (BET) inhibitor, VYN201. The clinical trial was …